Department of Dermatology, Harvard Medical School, Massachusetts General Hospital, Cutaneous Biology Research Center, Charlestown, Massachusetts, USA.
IPG Medical, IPG Photonics Corporation, Marlborough, Massachusetts, USA.
Lasers Surg Med. 2024 Feb;56(2):186-196. doi: 10.1002/lsm.23755. Epub 2024 Jan 16.
The use of ablative fractional lasers to enhance the delivery of topical drugs through the skin is known as laser-assisted drug delivery. Here, we compare a novel 3050/3200 nm difference frequency generation (DFG) fiber laser (spot size: 40 µm) to a commercially used CO laser (spot size: 120 µm). The objective is to determine whether differences in spot size and coagulation zone (CZ) thickness influence drug uptake.
Fractional ablation was performed on ex-vivo human abdominal skin with the DFG (5 mJ) and CO (12 mJ) lasers to generate 680 µm deep lesions. To evaluate drug delivery, 30 kDa encapsulated fluorescent dye was topically applied to the skin and histologically analyzed at skin depths of 100, 140, 200, 400, and 600 µm. Additionally, transcutaneous permeation of encapsulated and 350 Da nonencapsulated dye was assessed using Franz Cells.
The DFG laser generated smaller channels (diameter: 56.5 µm) with thinner CZs (thickness: 22.4 µm) than the CO laser (diameter: 75.9 µm, thickness: 66.8 µm). The DFG laser treated group exhibited significantly higher encapsulated dye total fluorescence intensities after 3 h compared to the CO laser treated group across all skin depths (p < 0.001). Permeation of nonencapsulated dye was also higher in the DFG laser treated group vs the CO laser treated group after 48 h (p < 0.0001), while encapsulated dye was not detected in any group.
The DFG laser treated skin exhibited significantly higher total fluorescence uptake compared to the CO laser. Additionally, the smaller spot size and thinner CZ of the DFG laser could result in faster wound healing and reduced adverse effects while delivering similar or greater amount of topically applied drugs.
利用消融性分数激光通过皮肤增强局部药物的递送被称为激光辅助药物递送。在这里,我们将一种新型的 3050/3200nm 差频产生(DFG)光纤激光(光斑大小:40µm)与商业 CO 激光(光斑大小:120µm)进行比较。目的是确定光斑大小和凝固区(CZ)厚度的差异是否会影响药物吸收。
用 DFG(5mJ)和 CO(12mJ)激光对离体人腹部皮肤进行分数消融,以产生 680µm 深的病变。为了评估药物递送,将 30kDa 包裹的荧光染料局部应用于皮肤,并在 100、140、200、400 和 600µm 的皮肤深度进行组织学分析。此外,使用 Franz 细胞评估包裹和 350Da 非包裹染料的经皮渗透。
DFG 激光产生的通道(直径:56.5µm)更小,CZ(厚度:22.4µm)比 CO 激光(直径:75.9µm,厚度:66.8µm)更薄。与 CO 激光治疗组相比,DFG 激光治疗组在所有皮肤深度(p<0.001)的 3 小时后包裹染料总荧光强度明显更高。48 小时后,DFG 激光治疗组的非包裹染料渗透也明显高于 CO 激光治疗组(p<0.0001),而在任何组中都未检测到包裹染料。
与 CO 激光相比,DFG 激光治疗的皮肤显示出明显更高的总荧光摄取。此外,DFG 激光的较小光斑大小和较薄的 CZ 可能导致更快的伤口愈合和减少不良反应,同时递送相似或更大量的局部应用药物。